Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
JAK Inhibitor Overview and Relevance to AD
Christopher Bunick, MD, PhD, and Ruth Ann Vleugels, MD, MPD, MBA, discuss the method of action for Janus Kinase (JAK) inhibitors and the pathology of atopic dermatitis (AD).
Now Viewing
EP: 1.JAK Inhibitor Overview and Relevance to AD
EP: 2.Comparing Current Treatment Agents for AD
EP: 3.Clinical Experience With JAK Inhibitor in AD
EP: 4.Experts Present Background on Long-Term Safety Study of Upadacitinib for AD
EP: 5.Experts on Results of Long-Term Safety Study of Upadacitinib for AD
EP: 6.Conclusions of Study on Long-Term Safety Study of Upadacitinib for AD
EP: 7.Assessing Risk Factors of Oral JAK Inhibitors and Traditional Agents
EP: 8.Experts Present Background on JAK Inhibitor vs Systemic Immunosuppressant Safety Study
EP: 9.Experts on Results of JAK Inhibitor vs Systemic Immunosuppressant Safety Study
EP: 10.Visualizing Safety Rates: Drug Events, Disease Baseline, and General Population Baseline
EP: 11.Box Warning and JAK Inhibitor
EP: 12.JAK Inhibitor Selectivity
EP: 13.Conclusions of JAK Inhibitor vs Systemic Immunosuppressant Safety Study
EP: 14.Evolving the Standard of Care for AD: Safety and Treatment Response
EP: 15.Transitioning Patients from Traditional Immunosuppressive Agents to JAK Inhibitor
EP: 16.AD Endotypes and Outcomes
EP: 17.Final Thoughts on JAK Inhibitor for AD
Recent Videos
Related Content
